Indeed, the targeting of angiogenesis by anti-VEGF antibody as well as TKI inhibitors has shown to impact not only vascularization architecture and permeability but also immune tumor texture as in other tumors [41,42]. The gene discussed is VEGFA; the disease is neoplasm.